merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>Eli Lilly's vials are a safer option with transparent pricing.</answer>

<question_number>2</question_number>
<answer>Eli Lilly's strategy challenges telehealth companies by offering a cheaper, safer alternative to compounded medications through LillyDirect.</answer>

<question_number>3</question_number>
<answer>Compounded weight-loss drugs are subject to far less oversight than traditionally approved medications.</answer>

<question_number>4</question_number>
<answer>Eli Lilly aims to regain market share by offering a cheaper alternative to its own product, potentially cannibalizing its own sales.</answer>

<question_number>5</question_number>
<answer>The FDA's shortage list allows compounding pharmacies to produce alternative versions of medications, which Eli Lilly aims to address by increasing supply.</answer>

<question_number>6</question_number>
<answer>N/A</answer>

<question_number>7</question_number>
<answer>Medicare patients may be more likely to use Eli Lilly's new offering, despite potential risks associated with weight-loss medications in older patients.</answer>

<question_number>8</question_number>
<answer>Eli Lilly's introduction of Zepbound vials may lead patients to perceive compounded tirzepatide as less safe.</answer>

<question_number>9</question_number>
<answer>The FDA lists tirzepatide as "in shortage", allowing compounding pharmacies to produce alternative versions.</answer>

<question_number>10</question_number>
<answer>Eli Lilly is using lower pricing as an indirect method to regain market share from compounding pharmacies.</answer>